Patents by Inventor Pei Gan

Pei Gan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12V MUTANTS
    Publication number: 20240101557
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: July 10, 2023
    Publication date: March 28, 2024
    Inventors: GENCHENG LI, LEI LIU, PEI GAN, CHANG MIN, ALEXANDER SOKOLSKY, XIAOZHAO WANG, QINDA YE, LE ZHAO
  • IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS
    Publication number: 20230357255
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: April 13, 2023
    Publication date: November 9, 2023
    Inventors: Xiaozhao Wang, Pei Gan, Taisheng Huang, Chao Qi, Ding-Quan Qian, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Fenglei Zhang, Le Zhao, Chunhong He
  • COMBINATION THERAPY COMPRISING AN FGFR INHIBITOR AND A KRAS INHIBITOR
    Publication number: 20230226040
    Abstract: The present disclosure relates to methods of treating cancer by administering a compound, which is a Fibroblast Growth Factor Receptor (FGFR) inhibitor, in combination with a Kirsten rat sarcoma (KRAS) inhibitor.
    Type: Application
    Filed: November 21, 2022
    Publication date: July 20, 2023
    Inventors: Alejandro Amador Arjona, Angela Abdollahi, Margaret Favata, Jonathan Rios-Doria, Hui Wang, Susan Wee, Pei Gan, Jeffrey C. Yang, Yong Li, Le Zhao, Chunhong He, Chunyin Marshall Law, Wenyu Zhu, Xiaozhao Wang, Wenqing Yao, Peter Niels Carlsen, Fenglei Zhang, Qinda Ye, Matthew S. McCammant, Rocco Policarpo, Artem Shvartsbart, Jeremy Roach, Gia Hoang, Bin Hu, Gencheng Li, Robert Susick, Padmaja Polam, Chao Qi, Alexander Sokolsky, Haolin Yin, Chang Min
  • Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
    Patent number: 11673894
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: June 13, 2023
    Assignee: Incyte Corporation
    Inventors: Xiaozhao Wang, Pei Gan, Taisheng Huang, Chao Qi, Ding-Quan Qian, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Fenglei Zhang, Le Zhao, Chunhong He
  • TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS
    Publication number: 20230056631
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: July 6, 2022
    Publication date: February 23, 2023
    Inventors: Pei Gan, Jeffrey Yang, Yong Li, Le Zhao, Chunhong He, Chunyin Marshall Law, Xiaozhao Wang, Wenqing Yao
  • FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS
    Publication number: 20220135570
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: October 13, 2021
    Publication date: May 5, 2022
    Inventors: Xiaozhao Wang, Peter Niels Carlsen, Pei Gan, Gia Hoang, Yong Li, Chao Qi, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Wenyu Zhu
  • VINYL IMIDAZOLE COMPOUNDS AS INHIBITORS OF KRAS
    Publication number: 20220064188
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: August 27, 2021
    Publication date: March 3, 2022
    Inventors: Peter Carlsen, Xiaozhao Wang, Alexander Sokolsky, Pei Gan, Rocco Policarpo, Wenqing Yao
  • TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS
    Publication number: 20210269434
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: January 8, 2021
    Publication date: September 2, 2021
    Inventors: Xiaozhao Wang, Wenyu Zhu, Jeffrey Yang, Alexander Sokolsky, Chunhong He, Zhenwu Li, Chao Qi, Yong Li, Pei Gan, Peter Carlsen, Gia Hoang, Heeoon Han, Chenyin Marshall Law, Fenglei Zhang, Padmaja Polam, Le Zhao, Liangxing Wu, Wenqing Yao
  • IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS
    Publication number: 20210139485
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: October 22, 2020
    Publication date: May 13, 2021
    Inventors: Xiaozhao Wang, Pei Gan, Heeoon Han, Taisheng Huang, Matthew S. McCammant, Chao Qi, Ding-Quan Qian, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Fenglei Zhang
  • FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS
    Publication number: 20200031835
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: July 3, 2019
    Publication date: January 30, 2020
    Inventors: Xiaozhao Wang, Peter Niels Carlsen, Pei Gan, Gia Hoang, Yong Li, Chao Qi, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Wenyu Zhu
  • IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS
    Publication number: 20190292188
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: February 26, 2019
    Publication date: September 26, 2019
    Inventors: Xiaozhao Wang, Pei Gan, Heeoon Han, Taisheng Huang, Matthew S. McCammant, Chao Qi, Ding-Quan Qian, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Fenglei Zhang
  • METHODS FOR DETECTING AND MODULATING THE SENSITIVITY OF TUMOR CELLS TO ANTI-MITOTIC AGENTS AND FOR MODULATING TUMORIGENICITY
    Publication number: 20160175339
    Abstract: Provided herein is a method of screening a tumour cell for resistance to a tubulin-binding agent, the method comprising detecting the expression of any one or more of class II, class III and class IVb ?-tubulin by the tumour cell, wherein the expression of any one or more of class II, class III and class IVb ?-tubulin indicates that the tumour cell has resistance or potential resistance to the tubulin-binding agent. Also provided are methods of modulating the sensitivity of a tumour cell Also provided is a method of modulating the tumorigenesis of a tumour cell.
    Type: Application
    Filed: November 25, 2015
    Publication date: June 23, 2016
    Inventors: Maria KAVALLARIS, Pei Pei GAN, Joshua Adam MCCARROLL
  • METHODS FOR DETECTING AND MODULATING THE SENSITIVITY OF TUMOR CELLS TO ANTI-MITOTIC AGENTS AND FOR MODULATING TURMORGENICITY
    Publication number: 20100159030
    Abstract: Provided herein is a method of screening a tumour cell for resistance to a tubulin-binding agent, the method comprising detecting the expression of any one or more of class II, class III and class IVb ?-tubulin by the tumour cell, wherein the expression of any one or more of class II, class III and class IVb ?-tubulin indicates that the tumour cell has resistance or potential resistance to the tubulin-binding agent. Also provided are methods of modulating the sensitivity of a tumour cell. Also provided is a method of modulating the tumorigenesis of a tumour cell.
    Type: Application
    Filed: September 8, 2009
    Publication date: June 24, 2010
    Applicant: NewSouth Innovations Pty Limited
    Inventors: Maria Kavallaris, Pei Pei Gan, Joshua Adam McCarroll